Decreased numbers of CD8 T RM 1 cells were documented as well (more so in the 600 mg group, with a mean of 2 cells in each sample), although these decreases did not reach statistical significance (Fig. 4c and Supplementary Fig. 2b ).
← all excerpts
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab.
1
—
—